Get Quartz in your inbox

Free daily briefing on global business news.

Roche's experimental lung cancer drug beat two rivals in a pivotal trial

Median overall survival reached 17.7 months with divarasib versus 12.0 months for sotorasib or adagrasib in a 338-patient phase III study

Roche said on Sunday its experimental lung cancer drug divarasib cut the risk of death by 44% relative to patients treated with sotorasib or adagrasib, based on a late-stage trial. The study enrolled patients with previously treated KRAS G12C-mutated non-small cell lung cancer.

Median overall survival was 17.7 months with divarasib, versus 12.0 months in the control arm, the company said. Divarasib also cut the likelihood of disease progression or death by 42%, and patients on it went a median of 9.8 months without progression, compared with........

© Quartz